14 completed, 5 active not recruiting, 4 terminated, 2 withdrawn. 23 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 14, Terminated 4, Active not recruiting 3, Withdrawn 2 |
| Phase 2 | 6 | Active not recruiting 4, Terminated 1, Withdrawn 1 |
Follow Unresectable Solid Neoplasm: new trials by email Literature Review of Unresectable Solid Neoplasm trials Research Report on Unresectable Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression Nivolumab - Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2021-09-21 | 2026-10-06 |
| Study of GNX102 in Patients With Advanced Solid Tumors GNX102 - Solid Tumor, Metastatic Cancer | Phase 1 | Terminated | GlycoNex, Inc. | 46 | 2020-07-29 | 2024-05-06 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 23 | 2018-09-24 | 2026-04-29 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2018-03-20 | 2023-10-17 |
| Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat - Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2018-03-16 | 2020-02-07 | |
| IACS-010759 in Advanced Cancers Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2017-11-13 | 2020-11-24 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study - Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma | Phase 1 | Completed | Northwestern University | 15 | 2017-05-23 | 2024-06-12 |
| APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401 - Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm | Phase 1 | Completed | Wake Forest University Health Sciences | 11 | 2017-04-28 | 2024-10-10 |
| Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery CDK Inhibitor AT7519, Laboratory Biomarker Analysis, Onalespib - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2016-09-30 | 2025-02-10 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 157 | 2016-08-15 | 2026-07-17 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Cisplatin, Methoxyamine, Pemetrexed Disodium - Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2016-03-08 | 2026-07-31 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab - Adult Solid Neoplasm, Bladder Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 11 | 2015-12-28 | 2026-10-19 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Advanced Malignant Solid Neoplasm, Anal Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 79 | 2015-10-21 | 2026-01-21 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study - Cirrhosis, Hepatitis B Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-01-30 | 2024-11-22 |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Sapanisertib, Ziv-Aflibercept - Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 83 | 2014-06-18 | 2025-10-20 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Dabrafenib, Laboratory Biomarker Analysis, Onalespib - BRAF V600E Mutation Present, BRAF V600K Mutation Present | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2014-05-29 | 2024-10-16 |
| Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Trametinib - Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver | Phase 1 | Completed | National Cancer Institute (NCI) | 46 | 2014-03-10 | 2025-02-13 |
| Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Solid Neoplasm, HIV Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2013-06-21 | 2023-01-10 |
Showing 20 of 25. Sign in to see all of them.
Neoplasm Metastasis (22) · Melanoma (6) · Triple Negative Breast Neoplasms (5) · Carcinoma, Renal Cell (4) · Pancreatic Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Lymphoma (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · HIV Infections (2) · Lung Neoplasms (2) · Lymphoma, T-Cell (2) · Ovarian Neoplasms (2)
Neoplasms (24) · Neoplastic Processes (22) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Neoplasms by Site (19) · Neoplasms by Histologic Type (14) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Urogenital Diseases (9) · Neoplasms, Glandular and Epithelial (8) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Genital Diseases (7)
Nivolumab (5) · CTLA-4 Antigen (3) · Ipilimumab (3) · pembrolizumab (3) · veliparib (3) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (2) · Irinotecan (2) · navitoclax (2) · trametinib (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide (1) · AZD8186 (1) · Biopsy (1) · CR011-vcMMAE (1) · Cetuximab (1)
National Cancer Institute (NCI) (15) · M.D. Anderson Cancer Center (5) · City of Hope Medical Center (1) · GlycoNex, Inc. (1) · Northwestern University (1) · Rutgers, The State University of New Jersey (1) · Wake Forest University Health Sciences (1)
United States (24) · Canada (2) · Australia (1) · Taiwan (1)
Aung Naing (2) · David S Hong (2) · Alison M Schram (1) · Andrea E Wahner Hendrickson (1) · Biren Saraiya (1) · Brian A Costello (1) · Christine L Hann (1) · Daniel J Renouf (1) · Funda Meric-Bernstam (1) · Haeseong Park (1) · Khanh T Do (1) · Lakshmi Rajdev (1) · Lillian L Siu (1) · Marianna Koczywas (1) · Mei-Chun Yang, PhD (1)
PMID 27729313, PMID 28428884, PMID 31533818, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33677480, PMID 33770291, PMID 34241781, PMID 34725215, PMID 35130943, PMID 35362047, PMID 35618285, PMID 35780243, PMID 35999229, PMID 36351402, PMID 36658425, PMID 37042037, PMID 37568622, PMID 37962072, PMID 39462179, PMID 39863139, PMID 39998620, PMID 40212844, PMID 40939237, PMID 41143139, PMID 42342409
P30CA016672 (4), UM1CA186689 (4), UM1CA186709 (4), U01CA062490 (3), UM1CA186644 (3), UM1CA186686 (3), UM1CA186691 (3), UM1CA186717 (3), ZIABC011078 (3), U01CA062487 (2), U01CA069912 (2), U01CA121947 (2), U01CA132123 (2), UM1CA121947 (2), UM1CA186690 (2)